ArticleMolecular therapy. Oncology2026

Point-of-care CAR-T cell manufacturing as a path to equity in cancer immunotherapy in a middle-income country.

Ha-My Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.